Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-11 4:46 pm Purchase | 2021-12-31 | 13G | Sonendo, Inc. SONX | ORBIMED ADVISORS LLC | 49 7.500% | 49 (New Position) | Filing History |
| 2022-02-11 4:42 pm Purchase | 2021-12-31 | 13G | RxSight, Inc. RXST | ORBIMED ADVISORS LLC | 1,062,500 3.900% | 1,062,500 (New Position) | Filing History |
| 2022-02-11 4:40 pm Purchase | 2021-12-31 | 13G | Protara Therapeutics, Inc. TARA | ORBIMED ADVISORS LLC | 671,741 6.000% | 671,741 (New Position) | Filing History |
| 2022-02-11 4:39 pm Sale | 2021-12-31 | 13G | PANDION THERAPEUTICS INC PAND | ORBIMED ADVISORS LLC | 0 0.000% | -1,040,825 (Position Closed) | Filing History |
| 2022-02-11 4:38 pm Sale | 2021-12-31 | 13G | Otonomy, Inc. OTIC | ORBIMED ADVISORS LLC | 0 0.000% | -2,480,800 (Position Closed) | Filing History |
| 2022-02-11 4:35 pm Unchanged | 2021-12-31 | 13G | NeuroPace, Inc. NPCE | ORBIMED ADVISORS LLC | 4,012,281 16.500% | 0 (Unchanged) | Filing History |
| 2022-02-11 4:31 pm Purchase | 2021-12-31 | 13G | Mereo BioPharma Group plc MREO | ORBIMED ADVISORS LLC | 6,063,345 5.590% | 1,544,989 (+34.19%) | Filing History |
| 2022-02-11 4:30 pm Sale | 2021-12-31 | 13G | MeiraGTx Holdings plc MGTX | ORBIMED ADVISORS LLC | 3,593,966 8.100% | -375,459 (-9.46%) | Filing History |
| 2022-02-11 4:29 pm Sale | 2021-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | ORBIMED ADVISORS LLC | 0 0.000% | -732,323 (Position Closed) | Filing History |
| 2022-02-11 4:27 pm Purchase | 2021-12-31 | 13G | Jounce Therapeutics, Inc. JNCE | ORBIMED ADVISORS LLC | 2,200,200 4.300% | 2,200,200 (New Position) | Filing History |
| 2022-02-11 4:26 pm Purchase | 2021-12-31 | 13G | Harpoon Therapeutics, Inc. HARP | ORBIMED ADVISORS LLC | 166,790 5.100% | 64,720 (+63.41%) | Filing History |
| 2022-02-11 4:23 pm Sale | 2021-12-31 | 13G | Gracell Biotechnologies Inc. GRCL | ORBIMED ADVISORS LLC | 5,970,672 8.900% | -23,882,692 (-80.00%) | Filing History |
| 2022-02-11 4:22 pm Sale | 2021-12-31 | 13G | Forte Biosciences, Inc. FBRX | ORBIMED ADVISORS LLC | 0 0.000% | -25,431 (Position Closed) | Filing History |
| 2022-02-11 4:21 pm Sale | 2021-12-31 | 13G | Standard BioTools Inc. LAB | ORBIMED ADVISORS LLC | 3,416,871 4.460% | -82,375 (-2.35%) | Filing History |
| 2022-02-11 4:19 pm Purchase | 2021-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX | ORBIMED ADVISORS LLC | 3,196,876 6.700% | 443,309 (+16.10%) | Filing History |
| 2022-02-11 4:18 pm Purchase | 2021-12-31 | 13G | Crescent Biopharma, Inc. CBIO | ORBIMED ADVISORS LLC | 3,424 4.300% | 3,424 (New Position) | Filing History |
| 2022-02-11 4:14 pm Purchase | 2021-12-31 | 13G | Applied Therapeutics, Inc. APLT | ORBIMED ADVISORS LLC | 2,100,681 8.000% | 433,856 (+26.03%) | Filing History |
| 2022-02-11 4:12 pm Sale | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | ORBIMED ADVISORS LLC | 158,245 7.900% | -42,376 (-21.12%) | Filing History |
| 2022-02-11 4:10 pm Sale | 2021-12-31 | 13G | Adverum Biotechnologies, Inc. ADVM | ORBIMED ADVISORS LLC | 0 0.000% | -484,525 (Position Closed) | Filing History |
| 2022-02-02 4:33 pm Unchanged | 2022-01-31 | 13D | Sierra Oncology, Inc. SRRA | ORBIMED ADVISORS LLC | 3,044,753 15.300% | 0 (Unchanged) | Filing History |